Satellos Bioscience (TSX:MSCL) Current Deferred Revenue: C$0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:MSCL Satellos Bioscience Inc TSX:MSCL
35 GF Score
Price C$12.29
! 1 Warning Sign
View Full Analysis

What is Satellos Bioscience Current Deferred Revenue?

Satellos Bioscience TSX:MSCL +1.07% 35 Current Deferred Revenue is C$0.00 Mil as of Mar. 2026. GuruFocus rates TSX:MSCL with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Satellos Bioscience's current deferred revenue for the quarter that ended in Mar. 2026 was C$0.00 Mil.

Satellos Bioscience Current Deferred Revenue Related Terms

Satellos Bioscience Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Satellos Bioscience's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Satellos Bioscience Current Deferred Revenue Chart

Satellos Bioscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Satellos Bioscience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSX:MSCL
35GF Score
Satellos Bioscience Inc TSX:MSCL
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of C$0.00 Mil mean?
Satellos Bioscience (TSX:MSCL) has a Current Deferred Revenue of C$0.00 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Satellos Bioscience and its competitors.
Is Satellos Bioscience's Current Deferred Revenue too high?
Satellos Bioscience's current Current Deferred Revenue is C$0.00 Mil. Overall, Satellos Bioscience has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Satellos Bioscience's Current Deferred Revenue compare to VRTX and REGN?
Satellos Bioscience's Current Deferred Revenue of C$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Satellos Bioscience and its competitors. Satellos Bioscience's current Current Deferred Revenue is C$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Satellos Bioscience stock overvalued right now?
Satellos Bioscience (TSX:MSCL) has a current Current Deferred Revenue of C$0.00 Mil. The current Current Deferred Revenue is C$0.00 Mil. Satellos Bioscience's overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Satellos Bioscience (TSX:MSCL), the current Current Deferred Revenue is C$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Satellos Bioscience Business Description

Other Exchanges MSLE:USA0IT:Germany
Address 200 Bay Street, Suite 2800, Royal Bank Plaza, South Tower, Toronto, ON, CAN, M5J 2J1
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.
35GF Score

Get the complete analysis for TSX:MSCL

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$12.29
Price